Vanguard Capital Wealth Advisors Acurx Pharmaceuticals, Inc. Transaction History
Vanguard Capital Wealth Advisors
- $78.9 Million
- Q1 2025
A detailed history of Vanguard Capital Wealth Advisors transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Capital Wealth Advisors holds 67,500 shares of ACXP stock, worth $26,325. This represents 0.03% of its overall portfolio holdings.
Number of Shares
67,500Holding current value
$26,325% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding ACXP
# of Institutions
27Shares Held
3.49MCall Options Held
100Put Options Held
0-
Sabby Management, LLC Upper Saddle River, NJ2.04MShares$797,3726.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA529KShares$206,4460.0% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$142,9640.08% of portfolio
-
Geode Capital Management, LLC Boston, MA171KShares$66,8790.0% of portfolio
-
Morgan Stanley New York, NY106KShares$41,4180.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $4.51M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...